Posts Tagged ‘liraglutide’

Liraglutide for Obesity Looking Like Diabetes Prevention

February 23, 2017 — An impressive new three-year study of 3 mg liraglutide for obesity (Saxenda) finds that this therapy provides a large reduction in the risk of developing diabetes in people who have prediabetes. Published yesterday in Lancet, investigators found an 80% reduction in the risk of progressing to diabetes. In a post-hoc analysis, they made further assumptions […]

A Rough Ride Despite Saxenda’s Success

October 31, 2016 — Over the last four years, four new obesity meds gained approval and only one lived up to expectations in the marketplace – the Saxenda brand of liraglutide 3 mg from Novo Nordisk. The company reported quarterly results last week. Saxenda sales, growing impressively, are on track to surpass $200 million for the year. Net profit for […]

Liraglutide Gains Momentum as Others Struggle in Obesity

July 11, 2016 — Now in the second year since approval of liraglutide for treating obesity, a pattern is becoming clear. While other obesity drugs struggle, liraglutide gains momentum. The momentum is evident in growing prescriptions for Saxenda (the brand name for liraglutide sold by Novo Nordisk at the dose for obesity). For the second quarter of 2016, total prescriptions for Saxenda […]

A Beauty Contest for Obesity Meds in JAMA

June 17, 2016 — A new study published this week in JAMA provides useful perspective on the safety and efficacy of the newer obesity meds now available for managing the chronic disease of obesity. Rohan Khera and colleagues integrated the results for 29,018 patients in 28 published clinical trials and concluded: Among overweight or obese adults, orlistat [Alli, Xenical], […]

Longer Lives with Weight-Sparing Diabetes Care

June 14, 2016 — A quiet revolution is taking shape in the form of weight-sparing diabetes care that helps people live longer. Yesterday new data were simultaneously published in the New England Journal of Medicine and presented at the American Diabetes Association (ADA) Scientific Sessions. The LEADER study showed that people treated for type 2 diabetes with liraglutide (Victoza) were 15% less […]

Elusive Billions for Obesity Care

May 2, 2016 — A recent headline in Wired shouted it out: “Diabetes drug that also treats obesity could make billions.” What followed was a mostly reasonable discussion of the risks and benefits of obesity treatment in the jocular tone typical of Wired. Alexa Kurzius explains her assessment of the potential for Saxenda (liraglutide) for obesity: Initially, weight loss was just […]

Calming the Brain’s Response to Food

April 4, 2016 — Your brain’s response to food is one of the key tools that your body uses to protect you from starving or losing too much weight. Even bad food starts looking really good and thoughts about food crowd out everything else in the brain. In a featured presentation at ENDO 2016, Olivia Farr and colleagues demonstrated that […]

Liraglutide CV Outcomes: A Milestone for Diabetes and Obesity

March 7, 2016 — A major new study shows that people treated with liraglutide for type 2 diabetes have fewer strokes, heart attacks, and deaths from heart disease. Six years ago, cardiovascular outcomes had doctors scratching their heads about diabetes and obesity drugs. A hearing on a flawed outcome study with sibutramine resulted in its withdrawal from the market. […]

Big Changes in Drugs for Diabetes and Obesity

January 31, 2016 — Some big changes are in the wind for drugs that treat diabetes and obesity. The biggest selling diabetes drug in the world — Lautus — is facing competition from a lower-priced, biosimilar form of this long-acting form of insulin. Newer drugs like Jardiance (empagliflozin) and Victoza (liraglutide) are growing robustly, valued for their profile for […]

Advancing Obesity Care in Step with Diabetes Care

January 7, 2016 — A new review of advances in obesity care adds reasons to think that these advances are synergistic with advances in diabetes care. John Dixon highlights three major advances in obesity care from 2015 and all of them relate to diabetes as well. Liraglutide. Dixon cites impressive evidence that this drug, newly indicated for obesity treatment, is […]